Skip to main content
Premium Trial:

Request an Annual Quote

Scienion Places Arrayers with Procognia, Courtagen for Chip Production

Premium

Scienion announced two deals in the past week. The Berlin-based company said that that Procognia, an Israeli glycobiology firm, has adopted its SciFlexarrayer for the production of glycoprotein arrays. In addition, Courtagen Life Sciences has selected the SciFlexarrayer to produce biochips for multiplex immunoassays.

Scienion sells a suite of non-contact, piezo-dispensing instruments for spotting arrays, all under the SciFlexArrayer brand. Its offering ranges from the entry-level DW model to the high-throughput S100. An updated version of its compact S1 model was released in May (BAN 5/29/2012).

Ashdod-based Procognia intends to use its SciFlexarrayer to manufacture its Multi Pad GlycoScope product, a lectin array platform for glycoanalysis. Procognia markets GlycoScope to pharmaceutical companies and research laboratories that are interested in studying the glycosylation structure of glycoproteins in potential new drugs.

Ilana Belzer, vice president of R&D and operations at Procognia, said in a statement that the firm decided to use the SciFlexarrayer because of the intstrument's "precise array spotting, reproducible results and the scalability capacity of the technology to meet any potential future production demands."

Courtagen

Like Procognia, Waltham, Mass.-based Courtagen Life Sciences recently adopted the SciFlexarrayer to produce its arrays. The company said in a statement that it will use the S11 model to produce its pQPDx Biochip protein immunoassay platform. Courtagen's QPDx Biochips run on its Avantra Q400 Biomarker Workstation, a benchtop multiplex biomarker analysis platform that Courtagen markets for research use, such as at a clinical trial site.

Kate Sheldon, director of product development at Courtagen, said in a statement that the firm decided to use Scienion's platform because of its ability to "consistently produce high quality arrays that meet our needs," and its "capacity to meet demand as our business grows."

In the same statement, Scienion CEO Holger Eickhoff noted that the firm will be collaborating with Courtagen via its newly established US office in Princeton, NJ. Scienion opened the US office last year to better serve its American and Canadian customers (BAN 12/6/2011).

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.